Compare RETO & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RETO | XBIO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.8M |
| IPO Year | 2016 | 2011 |
| Metric | RETO | XBIO |
|---|---|---|
| Price | $1.40 | $2.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.2M | 87.2K |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,976,411.00 |
| Revenue This Year | N/A | $2.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.04 |
| 52 Week Low | $0.09 | $1.90 |
| 52 Week High | $7.84 | $8.87 |
| Indicator | RETO | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 34.89 |
| Support Level | $0.54 | $2.07 |
| Resistance Level | $1.57 | $2.53 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.16 | -0.05 |
| Stochastic Oscillator | 55.94 | 5.00 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Equipment and technical service segment, and Craft beer segment. The company earns its revenue from the Equipment and technical service segment. Geographically, it derives a majority of its revenue from China.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.